Gemcitabine and carboplatin in  combination for the treatment of advanced, metastatic, non-small cell lung cancer

S. Nagel; Raffaele Califano; Nick Thatcher; Fiona Blackhall

doi:10.1517/14656566.8.18.3265

Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer

S. Nagel, Raffaele Califano, Nick Thatcher, Fiona Blackhall

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

Abstract

The universally accepted first-line treatment for advanced (stage IIIB effusion/IV) non-small-cell lung cancer in patients with a good performance status is a platinum drug in combination with one of gemcitabine, paclitaxel, vinorelbine or docetaxel. Although cisplatin is generally the favoured platinum agent, gemcitabine partnered with carboplatin is convenient to administer and has a favourable toxicity profile. Here, the pharmacology, preclinical and clinical data to support the use of this regimen for the treatment of advanced non-small-cell lung cancer is evaluated.

Original language	English
Pages (from-to)	3265-3275
Journal	Expert opinion on pharmacotherapy
Volume	8
Issue number	18
DOIs	https://doi.org/10.1517/14656566.8.18.3265
Publication status	Published - 26 Nov 2007

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1517/14656566.8.18.3265

Cite this

@article{81b754df843342b399508b220527c223,

title = "Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer",

abstract = "The universally accepted first-line treatment for advanced (stage IIIB effusion/IV) non-small-cell lung cancer in patients with a good performance status is a platinum drug in combination with one of gemcitabine, paclitaxel, vinorelbine or docetaxel. Although cisplatin is generally the favoured platinum agent, gemcitabine partnered with carboplatin is convenient to administer and has a favourable toxicity profile. Here, the pharmacology, preclinical and clinical data to support the use of this regimen for the treatment of advanced non-small-cell lung cancer is evaluated.",

author = "S. Nagel and Raffaele Califano and Nick Thatcher and Fiona Blackhall",

year = "2007",

month = nov,

day = "26",

doi = "10.1517/14656566.8.18.3265",

language = "English",

volume = "8",

pages = "3265--3275",

journal = "Expert opinion on pharmacotherapy",

issn = "1744-7666",

publisher = "Taylor & Francis",

number = "18",

}

TY - JOUR

T1 - Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer

AU - Nagel, S.

AU - Califano, Raffaele

AU - Thatcher, Nick

AU - Blackhall, Fiona

PY - 2007/11/26

Y1 - 2007/11/26

N2 - The universally accepted first-line treatment for advanced (stage IIIB effusion/IV) non-small-cell lung cancer in patients with a good performance status is a platinum drug in combination with one of gemcitabine, paclitaxel, vinorelbine or docetaxel. Although cisplatin is generally the favoured platinum agent, gemcitabine partnered with carboplatin is convenient to administer and has a favourable toxicity profile. Here, the pharmacology, preclinical and clinical data to support the use of this regimen for the treatment of advanced non-small-cell lung cancer is evaluated.

AB - The universally accepted first-line treatment for advanced (stage IIIB effusion/IV) non-small-cell lung cancer in patients with a good performance status is a platinum drug in combination with one of gemcitabine, paclitaxel, vinorelbine or docetaxel. Although cisplatin is generally the favoured platinum agent, gemcitabine partnered with carboplatin is convenient to administer and has a favourable toxicity profile. Here, the pharmacology, preclinical and clinical data to support the use of this regimen for the treatment of advanced non-small-cell lung cancer is evaluated.

U2 - 10.1517/14656566.8.18.3265

DO - 10.1517/14656566.8.18.3265

M3 - Article

SN - 1744-7666

VL - 8

SP - 3265

EP - 3275

JO - Expert opinion on pharmacotherapy

JF - Expert opinion on pharmacotherapy

IS - 18